News
Public · Published
Moderna Swings to 3Q Profit, Lifts Outlook as Covid-19 Vaccine Demand Stabilizes — Update
Moderna reported third-quarter profit of $162 million, versus a $200 million loss a year earlier, and revenue rose 29% to $1.31 billion, helped partly by stronger international Covid-19 vaccine sales. It raised its full-year revenue forecast as demand stabilized.
Published:
Updated:
What happened
Moderna reported third-quarter profit of $162 million, versus a $200 million loss a year earlier, and revenue rose 29% to $1.31 billion, helped partly by stronger international Covid-19 vaccine sales. It raised its full-year revenue forecast as demand stabilized.
Confirmed
Global impact / market context
The return to profit and higher revenue forecast suggest vaccine sales are currently supporting Moderna’s finances. If demand holds, that cash could help fund its expansion into cancer treatments; however, the article gives no revised forecast figure or evidence that these candidates will generate sales.
Analyst inference
Moderna’s results exceeded analysts’ expectations: they had expected a $1.10-per-share loss and $890.3 million in revenue. International vaccine sales contributed to the increase, while the company is also preparing regulatory submissions with Merck for a personalized melanoma vaccine after favorable late-stage study results.
Confirmed
What to watch
- Track whether international Covid-19 vaccine demand remains stable; a decline in sales could weaken revenue and reduce cash available to support Moderna’s broader development plans. Analyst inference
- Watch for Moderna and Merck’s planned regulatory submissions for the personalized melanoma vaccine; approval would be needed before it could be sold as a treatment. Proposed
- Look for details of the raised full-year revenue forecast and later financial results, which would show whether stronger vaccine sales are translating into sustained profitability. Analyst inference
Evidence
- Original source link unavailable